TransTech Pharma announced that the FDA has granted Fast Track designation for TTP488, a novel small-molecule orally active antagonist of Receptor for Advanced Glycation Endproducts (RAGE) being developed for the treatment of Alzheimer’s disease. TTP488 prevents the interaction of amyloid beta (Aβ), a material found in the cells of Alzheimer’s patients and a member of the immunoglobulin supergene family of molecules known as RAGE.
In a double-blind clinical trial in which data was compiled over 18 months, TTP488 slowed cognitive decline in patients with mild to moderate Alzheimer’s disease. There is substantial data suggesting that RAGE is involved in the pathogenesis of Alzheimer’s disease. Sustained Aβ interaction with RAGE at the blood brain barrier or in neuronal or microglial cells is an essential element of amyloid plaque formation and chronic neural dysfunction.
TTP488 is the first drug related to RAGE, a relatively new biological target in Alzheimer’s disease research.
For more information call (336) 841-7770 or visit www.ttpharma.com.